Top stories to read during Mental Health Awareness Month

Although millions of individuals in the United States are affected by mental health conditions, stigma can prevent people receiving the care and attention they need.

To mark Mental Health Awareness Month this May, Healio Psychiatry has compiled a list of most-read news articles relating to psychiatry written so far this year.

FDA approves esketamine nasal spray for hard-to-treat depression

The FDA has approved esketamine nasal spray, combined with an oral antidepressant, for the treatment of adults with treatment-resistant depression, according to a press release. Read more.

Experts declare physician burnout ‘a public health crisis’

Experts from leading U.S. health organizations deemed physician burnout “a public health crisis” in a recent report. Read more.

Physical activity protects against depression

Robust evidence supports a protective relationship between objectively-assessed physical activity and major depression risk, according to findings from a two-sample mendelian randomization study. Read more.

Source: Adobe Stock

FDA approves Adhansia XR for ADHD

The FDA has approved Adhansia XR extended-release capsules CII, a central nervous system stimulant, for the treatment of ADHD in certain patients aged 6 years and older, according to a press release. Read more.

Anti-inflammatory agents improve antidepressant effects

Certain anti-inflammatory drugs improved antidepressant treatment effects and depression symptoms without increasing risk for adverse events, findings from a systematic review and meta-analysis showed. Read more.

FDA approves first drug exclusively intended for female postpartum depression

The FDA recently approved Zulresso, an IV injection that is a positive allosteric modulator of gamma-aminobutyric-acid type A receptors, for treatment of postpartum depression in women aged 18 to 45 years, according to a press release from its manufacturer. Read more.